Novo Nordisk A/S (NVO) Stock Price & How to Invest

Novo Nordisk (NVO) is a Danish pharmaceutical company and a global leader in diabetes and obesity care. Its franchise centers on GLP-1 receptor agonists, most notably semaglutide, sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management. Novo Nordisk also holds a long-standing leadership position in insulin and broader diabetes therapies, and maintains smaller franchises in rare blood and endocrine disorders. The company is headquartered in Bagsvaerd, Denmark, and is controlled by the Novo Nordisk Foundation through a dual-share structure. US investors typically access it through the NVO American Depositary Receipt listed on the New York Stock Exchange, which represents the Danish B shares. The explosive demand for GLP-1 drugs for both diabetes and weight loss has made Novo Nordisk one of Europe's most valuable companies, while also straining its manufacturing capacity for injectable medicines.

The growth phase has stalled. Revenue rose from about DKK 232 billion in 2023 to about DKK 309 billion in 2025, but growth slowed to about 2% year over year in Q2 2026, and analysts expect full-year 2026 revenue of about DKK 301 billion, slightly below 2025, before roughly flat 2027. Eli Lilly's tirzepatide has taken share in the US, and in October 2026 Lilly's oral obesity drug Foundayo won a positive opinion from the European Medicines Agency's committee, adding pill competition in Novo's home region. Margins remain very high (operating margin about 43% and net margin about 35% over the trailing twelve months), and Novo has been buying back shares. Q3 2026 results are scheduled for November 4, 2026.

Novo Nordisk is heavily concentrated in a single drug class, so any clinical setback, safety signal, or faster-than-expected competition from Eli Lilly's tirzepatide (Mounjaro, Zepbound) and newer entrants directly threatens the core franchise; 2026 has shown that risk playing out, with revenue growth near 2% in Q2 and consensus calling for a small decline for the year. Oral competitors, including Lilly's Foundayo (backed by an EMA panel in October 2026) and Viking's Phase 3 pill, raise the pressure further. Manufacturing capacity has been a persistent constraint, limiting how much demand it can serve. US drug pricing, payer coverage decisions, and potential price negotiation add reimbursement risk to its largest market. As an ADR, NVO carries Danish krone currency exposure and is influenced by European regulation. Patent expiries and the eventual arrival of biosimilar or generic competition loom over the long-term semaglutide economics. Debt has also risen with the capacity build (about DKK 140 billion against about DKK 45 billion of cash at mid-2026).

12 analysts publish price targets on NVO, averaging $45.78 against a $38.83 price as of October 2026, or +17.9%. The published targets run from $39.91 to $62.03, a moderate spread, and the ratings split 3 buy, 10 hold, 1 sell. Over the last six months there have been 0 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full NVO forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Novo Nordisk A/S. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. GLP-1 obesity and diabetes demand. Semaglutide-based products (Ozempic, Rybelsus, Wegovy) sit at the center of a structural shift in how obesity and type 2 diabetes are treated. The most optimistic published target, $62.03, assumes this works close to its best case.

The case against. Novo Nordisk is heavily concentrated in a single drug class, so any clinical setback, safety signal, or faster-than-expected competition from Eli Lilly's tirzepatide (Mounjaro, Zepbound) and newer entrants directly threatens the core franchise; 2026 has shown that risk playing out, with revenue growth near 2% in Q2 and consensus calling for a small decline for the year. The most pessimistic target, $39.91, is roughly what NVO is worth if this bites instead.

Read the full bull and bear case on NVO, including what would have to change to break either one. Walnut is not an investment adviser.

Yes. Novo Nordisk A/S (NVO) has had one share split in the last 10 years:

• 2:1 on September 20, 2023, so every share held became 2 shares.

A split changes the share count and the price per share and leaves the value of a holding unchanged. Someone holding $1,000 of NVO the day before the 2:1 split held $1,000 the day after, in more shares at a proportionally lower price. Historical prices from before the date are normally shown split-adjusted, which is why a long-run chart shows no cliff.

Splits matter mainly because they make older price figures confusing to compare by hand, and because a board choosing to split is usually signalling that the price has run up far enough to feel awkward for smaller buyers. Neither is a reason to buy or sell.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Novo Nordisk A/S's investor relations page or your broker.

• Revenue (TTM): ~DKK 329 billion (+2% YoY in Q2 2026)
• Revenue (2026 consensus): ~DKK 301 billion
• Operating margin (TTM): ~43%
• Net margin (TTM): ~35%
• P/E (trailing / forward): ~9x / ~11x
• Dividend yield: ~4.6% (~$1.80 per ADR, ~43% payout)
• Market cap: ~$173 billion
• Listing: NYSE ADR representing Danish B shares

Novo Nordisk once commanded a premium pharma multiple on the strength of GLP-1 growth; at about 9x trailing and 11x forward earnings in October 2026 it now trades at a discount that reflects slowing sales and share loss to Eli Lilly. Trailing net income is lifted by an unusually large Q1 2026, which is one reason forward earnings estimates sit below trailing ones. Figures are reported in Danish kroner (market cap and the ADR dividend in dollars) and should be verified against the latest filings; Q3 2026 results are due November 4.

These are the investment theses NVO naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Other names that sit close to NVO: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get NVO exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so NVO sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where NVO fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Novo Nordisk (NVO) is a large-cap European pharma whose value hinges on the GLP-1 obesity and diabetes franchise. In a portfolio it behaves as a healthcare growth holding levered to one therapeutic class, with high margins and strong cash generation balanced against competition from Eli Lilly, manufacturing capacity limits, and pricing and reimbursement pressure. It is a currency-exposed ADR, not a domestic blue chip. After a long derating it trades near 9x trailing and 11x forward earnings with a dividend yield around 4.6% as of October 2026, a valuation that prices in flat-to-lower growth rather than the expansion of 2023-2024.

Whether NVO is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is NVO a buy or a sell?, and where the stock could go from here in the NVO stock forecast.

For income investors, whether NVO pays a dividend and how the payout looks is covered in does NVO pay a dividend? And to weigh NVO against a peer, read the full side-by-side comparisons: NVO vs LLY and NVO vs AMGN.